Raul Rodriguez, MD
Addiction Psychiatry · Delray Beach, FLNPI 1467475913
Payments from drug & device makers
Across 550 payments — averaging $179.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Livanova USA, Inc.$55K
- Brainsway USA Inc$22K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$12K
- AbbVie$2K
- Otsuka America Pharmaceutical, Inc.$1K
- Vanda Pharmaceuticals Inc.$1K
- plus $5K from 27 others
What the payments were for
- Consulting fees$8,79928%
- Food & beverage$22,37472%
- Education$170%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Livanova USA, Inc. | 21 | $55,418 |
| Brainsway USA Inc | 24 | $21,914 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $12,376 |
| AbbVie(2 entities) | 119 | $1,616 |
| Otsuka America Pharmaceutical, Inc. | 70 | $1,239 |
| Vanda Pharmaceuticals Inc. | 46 | $1,034 |
| Alkermes, Inc. | 28 | $518 |
| Teva Pharmaceuticals USA, Inc. | 22 | $449 |
| Lundbeck LLC | 17 | $419 |
| Almatica Pharma LLC | 25 | $385 |
| Johnson & Johnson | 18 | $379 |
| Corium, LLC | 28 | $353 |
| Indivior Inc. | 17 | $346 |
| Orexo US, Inc. | 18 | $330 |
| Neurocrine Biosciences, Inc. | 12 | $325 |
| Takeda Pharmaceuticals U.S.A., Inc. | 14 | $300 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 13 | $284 |
| Supernus Pharmaceuticals, Inc. | 7 | $234 |
| Axsome Therapeutics, Inc. | 7 | $196 |
| Braeburn Inc. | 9 | $190 |
| E.r. Squibb & Sons, L.L.C. | 9 | $174 |
| Bausch Health US, LLC | 5 | $98 |
| Eisai Inc. | 5 | $86 |
| Idorsia Pharmaceuticals US Inc | 3 | $60 |
| Gilead | 2 | $39 |
| Neuronetics, Inc. | 1 | $36 |
| Neos Therapeutics, LP | 2 | $30 |
| Tempus AI, Inc | 1 | $27 |
| Validus Pharmaceuticals LLC | 1 | $18 |
| Novo Nordisk | 1 | $17 |
| Sunovion Pharmaceuticals Inc. | 1 | $16 |
| Merck | 1 | $16 |
| Hikma Pharmaceuticals USA | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Brainsway Deep TMS$17,844
- Brainsway Deep TMS System$600
- QELBREE$121
How this compares
$98,937 in reported general payments places this provider in the 90th percentile of 29 addiction psychiatry providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 15 | $166,975 |
| Invega SustennaPaliperidone Palmitate | 22 | $69,429 |
| CaplytaLumateperone Tosylate | 21 | $34,045 |
| VraylarCariprazine Hcl | 21 | $29,741 |
| TrintellixVortioxetine Hydrobromide | 25 | $15,328 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 87 | $14,877 |
| Lurasidone Hcl | 46 | $13,051 |
| VyvanseLisdexamfetamine Dimesylate | 19 | $10,746 |
| Vilazodone Hcl | 104 | $10,671 |
| SuboxoneBuprenorphine Hcl/Naloxone Hcl | 18 | $9,417 |
| Aripiprazole | 136 | $6,246 |
| Buspirone Hcl | 302 | $5,028 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 162 | $4,869 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 26 | $4,591 |
| Varenicline Tartrate | 14 | $3,583 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo | $449 | $166,97515 claims |
| Johnson & JohnsonInvega Sustenna | $379 | $69,42922 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $284 | $34,04521 claims |
| AbbVieVraylar | $1,616 | $29,74121 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $300 | $26,07444 claims |
| Hikma Pharmaceuticals USABuprenorphine-Naloxone, Buprenorphine Hcl | $15 | $17,208151 claims |
| Indivior Inc.Suboxone | $346 | $9,41718 claims |
| Almatica Pharma LLCSertraline Hcl | $385 | $1,768228 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 29 addiction psychiatry providers in Florida.
Other addiction psychiatry in Delray Beach
- Curtis PhillipsDelray Beach$2K
- Zaheer AslamFort Myers$1.8M
- Julio Castro GayolPalmetto Bay$442K
- Jason FieldsNew Port Richey$26K
- Edward BariasJupiter$21K
- Mary SheehanTampa$16K
- Aldo MoralesFort Lauderdale$13K
- Krishan BatraOdessa$10K
- Lawrence WeinsteinSt Petersburg$6K
- Syed ZaidiPinellas Park$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.